newsfilter
← Latest News
Business Wire·

Cerus Corporation to Participate in the 17th Annual Craig-Hallum Alpha Select Conference

CERS
  • Cerus Corporation management will host one-on-one investor meetings at the 17th Annual Craig-Hallum Alpha Select Conference in New York City on Tuesday, November 17.
  • The company is headquartered in Concord, California, & aims to become the preeminent global blood products company.
  • Cerus develops technologies & supplies pathogen-protected blood components to blood centers, hospitals, & patients.
  • The INTERCEPT Blood System for platelets & plasma holds both CE mark & FDA approval globally.
  • In the U.S., the INTERCEPT Blood System for Cryoprecipitation is approved for producing Pathogen Reduced Cryoprecipitated Fibrinogen Complex to treat bleeding associated with fibrinogen deficiency.
  • The INTERCEPT red blood cell system is under regulatory review in Europe & in late-stage clinical development in the U.S.